This study evaluates the addition of oral dydrogesterone to standard treatment in the treatment of preterm labor. Half of participants will receive oral dydrogesterone and standard treatment, while the other half will receive oral placebo and standard treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
dydrogesterone capsule
placebo capsule
Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand
latency period
time from preterm labor to delivery
Time frame: 13 weeks
preterm delivery less than 34 weeks
percentage of delivery less than 34 weeks
Time frame: 10 weeks
preterm delivery less than 37 weeks
percentage of delivery less than 37 weeks
Time frame: 13 weeks
neonatal complications
percentage of newborn with RDS, IVH, NEC, death
Time frame: 13 weeks
side effects
percentage of side effects such as headache, nausea/vomiting
Time frame: 13 weeks
compliance
percentage of complete drug use
Time frame: 13 weeks
satisfaction
percentage of good satisfaction
Time frame: 13 weeks
Time to the recurrence of uterine contractions
Time to the recurrence of uterine contractions
Time frame: 13 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.